In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
Influenza A is a viral infection responsible for seasonal flu outbreaks. The content focuses on leveraging immunoinformatics and agent-based modeling to design and assess Influenza A vaccines more efficiently, aiming to combat the challenges posed by this infectious disease, including rapid viral mutations.
How can we optimize Influenza A vaccine design by specifically targeting the protein sequences of HA, NA, and M2, critical components of the virus?
IMMUNOINFORMATICS: Recombinant Vector Design
Epitope selection and vaccine design – Workflow of bioinformatics tools to optimize epitopes
AGENT-BASED MODEL: Dynamic simulations
Immune and influenza disease stimulation – Virtual patient simulations, predicting vaccine efficacy
In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.
In silico SD Bioequivalence trial to replace clinical trial
In silico clinical trial to support label extension.
Connect with our in silico team of experts to discuss AI solutions and advanced modeling and simulation for the Pharma and Life Science industries and hyper accelerate your success
Our Locations
Copyrights 2024 Ikiminds Pvt Ltd. All Rights Reserved